Lloyds Banking Investors - LLOY

Lloyds Banking Investors - LLOY

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Lloyds Banking Group Plc LLOY London Ordinary Share GB0008706128 ORD 10P
  Price Change Price Change % Stock Price Last Trade
-0.81 -2.12% 37.32 16:35:24
Open Price Low Price High Price Close Price Previous Close
38.14 35.805 38.15 37.32 38.13
more quote information »
Industry Sector

Top Investor Posts

portside1: If they hit investors then the country will get worse not better Private investors will pull out .If he does hit capital gains then he is out to destroy capitalism'
minerve 2: Lombard: Investors should fear the fantastical float valuation of veterinary services company IVC Evidensia. If IVC arrives on the market anywhere close to its mooted valuation, investors are being served a dog’s dinner. Do we ever get anything else from today's IPOs?
xxxxxy:  Ben in London. Photo: Kirsty Wigglesworth/APFor years UK stocks have been underperforming, under-owned, and unloved.But now, as the Brexit end game looms and a possible global COVID recovery beckons, analysts think that could be about to change."If people get more confident on the prospect of normalisation, if we get some more hopefully positive news on Brexit, then you should see the UK market going well," Themis Themistocleous, UBS Wealth Management's chief investment officer, told journalists on an outlook call on Tuesday.Analysts at UBS, Morgan Stanley, and Citi have all recently advised clients to buy into UK equities, arguing that the market could be a surprise performer in 2021.Morgan Stanley said in a note sent to clients on Sunday that the FTSE 100 (^FTSE) could rally by 17% next year. Citi this week told investors to consider an "aggressive" short-term bet on UK equities, Bloomberg reported. Analysts at the US bank said Britain's stock market was likely to outperform the US over the next few months.READ MORE: UK secures 5 million doses of Moderna's COVID-19 vaccineThe bullish bets are notable given the poor run British equities have been on since the Brexit referendum. The FTSE 100 is more or less at the same level it was on the day of the 2016 vote. Meanwhile, the S&P 500 (^GSPC) has risen 66% over the last four years and the MSCI World (MWS=F) has rallied over 45%.?The FTSE is more or less flat when compared to June 2016. Photo: Yahoo Finance UK"If we look at the UK market, it is trading at about a 25% discount to global markets," Themistocleous said. "The historical average has been about 10%, obviously for good reasons."If you look at the hit to the economy from COVID, it's been more severe than some of the other countries. We had the uncertainty about Brexit. There's been a number of things overhanging the UK economy."London-listed stocks have also suffered due to a comparative lack of tech on the market. Technology has been the stand out sector globally over the last decade. The FTSE 100 is dominated by oil and materials companies, financials, and domestic retail, none of which have performed well in recent years.Moving forward, this equity imbalance may actually work in the UK's favour. Recent positive COVID-19 vaccine news has prompted a historic global rotation away from growth stocks - like tech - towards value stocks - solid companies trading below their book value, typically in industries like banking or insurance.The years-long underperformance of UK stocks and the proliferation of steady, mature businesses that value investors love means the FTSE 100 looks well placed to benefit from the rotation."UK equities look extremely cheap versus peers and are very positively correlated to global value trends," a team of Morgan Stanley analysts wrote in a 2021 outlook note.READ MORE: COVID-19 vaccine: BioNTech and Pfizer report 90% effectiveness in trialsThis dynamic was already on show last week. The FTSE 100 had fallen 20% so far this year prior to Pfizer and BioNTech's positive vaccine news. However, the index rallied 7% last week after the pair said their vaccine candidate had a 90% effectiveness rate. Rupert Thompson, chief investment officer at Kingswood, said the UK was a "notable outperformer" globally.The fundamental outlook for many UK-listed businesses also looks strong. While tech businesses have benefited from the world being stuck indoors during the pandemic, a possible global recovery next year should benefit industrial companies and sectors like banking and energy that largely mirror the health of the economy."As we're coming out and the economy is starting to normalise, you would expect those sectors to lead the recovery," Themistocleous said. "If you look at earnings expectations for those sectors, they're likely to be a lot stronger than technology or the more defensive parts of the economy. You have earnings momentum in your favour."Morgan Stanley believes earnings per share on the FTSE 100 could grow by 35% next year, outpacing the 30% expected from the MSCI Europe index."If you look at the expected dividend yield from the UK, it is still very attractive," Themistocleous added. "The market is around 4% in an environment where it's very, very difficult to get yield, which is another aspect I think of with the UK equity market."The one hiccup for share prices could be the pound. FTSE 100 companies make around 70% of their earnings overseas, meaning any rally for the pound hurts bottom lines. A positive resolution to Brexit trade talks could spark such a rally but Themistocleous thinks UK stocks are still worth a punt."Net-net we still think the UK can still perform well in combination of earnings recovery, more confidence, multiple expansion, and closing the gap in terms of valuation relative to the other markets," he said.... Yahoo Finance
sikhthetech: Gecko #339 "demand and supply" Humans naturally move to where there is work to help their families. Around 20yrs ago, East European nations joined the EU, thus allowing freedom of movement. Many came here. At the same time there was a more favourable environment for Buy to Let investors, so there was a boom in Btl buying. That favourable environment no longer exists. With Brexit, the tables have turned. The question is how many will now decide to move to EU. I think in the future there will be fewer btl investors and reduced net migration. The market has been supported by Help to Buy scheme, Stamp Duty hol and furloughing. I suspect people on furlough have taken the 'unexpected' extra free time to take mortgage payment hols and used the 'unexpected' time and money to refurb their homes or go on hol. Furlough, Help to buy for 2nd homes and Stamp Duty hol all end on 31st March, less than 5 months away.
utyinv: Gaffer73, Many investors don’t trade shares like day traders, they invest and expect the income to come in. Not everyone invests like we may invest, watching the markets daily, some people have busy lives. If you were buying speculative high risk shares maybe you will be watching attentively, but many invest in what are regarded as Blue Chip secure stock that are income generating and thus constantly growing. What about the millions who invest in pensions/funds who cannot sell a particular stock? For the majority of investors mentioned above, they expect fluctuations but not a reduction in capital value of 60%, not from supposedly blue chip secure stock anyway. Antonio’s stewardship has been woeful. A cash generating machine that is a bedrock of capital investments for many, has performed badly and a lot of which is as a result of poor management and a lack of concern for the owners of the Company, the shareholders, many of whom are not speculative day traders but stoic capital investors whose main purpose is to earn an income.
xxxxxy: From FOOL, YAHOO Finance...Anyone who owns shares in Lloyds Banking Group (LSE: LLOY) has had a rough year. Lloyds' share price has fallen by more than 50% since the start of 2020. The coronavirus pandemic has triggered fears that banks could face a sharp rise in bad debt.The bank's business is totally focused on the UK, which is now officially in recession. We're all hoping the UK will bounce back quickly. But the reality is that we don't know how long it will take for economy to recover.However, given what we do know, I think there are good reasons to believe Lloyds shares are too cheap at current levels.#1: the bad news is in the priceIt's important to remember markets always look forward. I believe Lloyds shares are already priced for bad news. In its half-year results at the end of July, Lloyds warned investors it's planning for bad debts of around £5bn this year. That's nearly four times more than the £1.3bn reported for 2019.At this stage, Lloyds' bad debt numbers are only estimates. Things may turn out better than this. Recent data from estate agents and car dealership certainly suggest consumers are starting to spend again.However, my sums suggest that if Lloyds' central forecasts are correct, the bank's tangible net asset value would fall from 51.6p per share to around 44.5p per share. With the stock trading at just 28p as I write, I think that still leaves a healthy margin of safety for investors.#2: Lloyds is still one of the best performersLloyds also has another attraction, in my view. It's more profitable than UK-focused rivals such as NatWest Group (the new name for RBS). During the first half of the year, Lloyds generated a net interest margin - a measure of lending profitability - of 2.59%. The equivalent figure for NatWest Group was just 1.62%.One reason for this is that Lloyds' costs are lower. During the first half of the year, the bank's costs accounted for 55.2% of its income, compared to 62.8% at NatWest Group. Lloyds' lower costs should mean that profits bounce back more quickly.Lloyds was the most profitable of the UK's big high street banks before the coronavirus pandemic. I don't think this will change. That should help the bank's profits bounce back more quickly than at less profitable peers.#3: Lloyds share price suggests 5.5% dividend yieldBanks were forced to suspend dividend payments by the UK regulator earlier this year. Several made it clear they could have paid, but had no choice but to comply.The news was a bitter blow for income investors. But I'm pretty confident the dividend will return in 2021. Analysts' forecasts suggest a payout of 1.58p per share next year, giving a forecast yield of 5.5%. That looks realistic to me. Despite this year's disappointment, I believe Lloyds will remain a solid choice for income seekers,Ultimately, sentiment towards the UK economy is dire at the moment. The Lloyds share price reflects this. But, at some point, things will improve. In my view, now's probably a good time to buy some shares and tuck them away for the future. I don't think they'll get much cheaper than this.The post Has the Lloyds share price fallen too far? Here's what I'd do now appeared first on The Motley Fool UK.
xxxxxy: Payments technology provider Form3 has completed its Series C funding round, first announced last month, with the inclusion of banking groups Lloyds and Nationwide.The banks took part in the $33m fundraise alongside new VC investor 83North and existing investor Draper Esprit, and both banks are also exploring strategic partnerships to use Form3's payments technology.With the addition of Lloyds and Nationwide as shareholders, Form3 now has three major financial services groups as investors, with Barclays taking part in the fintech's Series A in 2017."Form3 for us is a really exciting opportunity to contribute to building a new domestic payments architecture for the group," Otto Benz, director of payments technical services at Lloyds Banking Group told AltFi, pointing to the New Payments Architecture, the UK payments industry's proposed new way of organising payments between banks.h7"Clearly that's a big step for a banking group the size of Lloyds Banking Group, and it's going to be careful as you go, in terms of how we implement that, but that's the strategy, that's why we want to do it because we see the opportunity for our customers in increasing  the security and resilience in our infrastructure."Nationwide's chief operating officer Patrick Eltridge told AltFi that the building society's payments work with Form3 is still under development and that "there are multiple opportunities around how we might work together and we're looking very carefully at those at the moment, so we expect to be clear about our future plans before too long."On Nationwide's investment in Form3, Eltridge said there was a "compelling difference" between the fintech and other providers in the industry. "We've been conducting a very broad review of participants in the payments industry, and we saw the best combination of truly modern cloud-native technology along with an approach and mindset in building an appropriately lean and easy to deploy service built to be highly resilient.""We think [Form3] has a great future ahead of it."While bringing on so many big industry players as strategic investors might close doors in other areas of financial services, Form3 CEO Michael Mueller told AltFi he's confident the startup isn't closing any doors."Where banks differentiate is actually more in the front end, and that's clearly not our expertise or domain.""What we're seeing is actually that banks benefit the more that come on board our platform, whether through operating leverage or the development of features like the adoption of the new payments architecture."And with three major banks already on board, Form3 is well on its way.hTtps://www.form3.tech/... SourceAltFi
maxk: From the ticker: Gilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street 03/08/2020 12:29pm Dow Jones News Johnson and Johnson (NYSE:JNJ) Intraday Stock Chart Monday 3 August 2020 Click Here for more Johnson and Johnson Charts.By Charley Grant Researchers are racing to develop a Covid-19 vaccine, and investors are in a mad dash to profit from it. The financial side of this exercise is likely to run into trouble. Promising news in the hunt for a vaccine continues to pour in. Several companies have revealed encouraging, albeit preliminary, data in clinical trials, and the U.S. government has its wallet wide open to defray research and manufacturing expenses. GlaxoSmithKline and Sanofi said Friday that the U.S. government will pay up to $2.1 billion to develop and manufacture a Covid-19 vaccine. Other companies such as Moderna and AstraZeneca have received similar contracts. These deals include the upfront purchase of hundreds of millions of doses if trials prove successful. Heavyweights Merck & Co. and Johnson & Johnson also have candidates in development. While it won't be clear if any candidate is successful until at least the fall, investors aren't waiting around. A broad index of biotechnology stocks has surged 65% since March. Within that group, the Covid-19 vaccine makers have led the way, both large and small. The gain in market value for these companies since the spring matches the total value of some major drugmakers that generate roughly $20 billion in annual sales. There are ample reasons for caution, despite the clearly positive news. For starters, most drug candidates in development don't reach the market. Huge research investments won't change that reality. And, even if successful, pricing power may not be as strong as investors are hoping. The first round of doses are already paid for and priced into stocks. Pfizer and its partner BioNTech, which didn't take any government research funding, have a contract to deliver 100 million doses for a total of $1.95 billion. That comes out to about $39 per two-dose treatment. Companies that hope to charge more than that over the long term will need to meet a very high safety and efficacy bar to make their case -- especially those that took public funds upfront. While drug pricing hasn't attracted much scrutiny this election cycle, it has been a recurring theme in American politics with major consequences for shareholders. That dynamic likely makes visions of windfall profits more dream than reality. Granted, some risk-taking is always necessary to make money in biotech. And story stocks have a way of maintaining their upward momentum while hopes for the future are still intact -- particularly in today's euphoric investing environment. But investors shouldn't forget that hot drug stocks can suddenly plunge even if things go according to plan. Gilead Sciences shares surged nearly 25% from March to April as anticipation built for its antiviral Covid-19 treatment remdesivir, but the stock has since lost nearly all of that ground. Those losses came despite a string of successes: The drug has been authorized for emergency use, and Gilead began selling it this summer after donating its initial supply. Last week, the company increased the midpoint of its 2020 adjusted profit guidance to $6.95 a share from $6.25. Don't dismiss the possibility that Gilead's descent will repeat itself on a much larger, uglier scale. Write to Charley Grant at charles.grant@wsj.com
freddie01: Lloyds Banking facing near perfect storm of challenges, say analysts Analysts at Shore Capital, however, encouraged investors to look through this disappointing set of results and “reflect on the strength of the balance sheet and scope for profits to improve materially in future as the economy recovers” Lloyds Banking Group PLC (LON:LLOY) is facing a near “perfect storm” of challenges, according to analysts, and glimmers of hope are “few and far between”. Heading into the results, the consensus forecast had been for a negligible loss of £13mln, having announced an adjusted £558mln profit in the first quarter. But Britain’s biggest mortgage lender swung to an underlying loss before tax of £839mln in the first half of the year, which was worse than investors and the City expected. “This is primarily due to much higher than expected impairments as the group has adjusted its macro-economic assumptions to reflect a more challenging outlook,” said analyst Gary Greenwood at Shore Capital, with Lloyds lifting bad loan impairment charges by £2.4bn to £3.8bn. A statutory loss before tax of £676mln, which compared to expectations of a £31mln loss, saw a further drag from £70m of restructuring charges and £233mln of gains related to market volatility and other items. Greenwood added that Lloyds earlier assumptions “seemed optimistic” and pointed out that much of the additional provision obtain transitional relief “so there is a delayed impact to capital”. Richard Hunter, head of markets at Interactive Investor, said: “The current environment is proving to be a hard slog for Lloyds, and the difficulties are unfortunately set to continue. “Since its last update, Lloyds estimates that the economic outlook has deteriorated further, partly because of the immediate impact of the pandemic in its second quarter, but also due to the likelihood of significantly higher defaults on loans in the next few months as various government support schemes subside. “The wider challenges are exacerbated given the bank’s perceived status as a barometer of the UK economy. With GDP growth remaining under pressure and the unemployment rate potentially yet to peak, the uncertainty around Brexit negotiations takes on additional significance given an already faltering economy.” More cautious than Barclays UBS analyst Jason Napier said Lloyds’ new guidance “looks cautious when compared with Barclays”, which released results a day earlier. FTSE 100 rival Barclays had issued what felt like a cautious outlook for the second half of the year, stressing its dependence on a strong recovery in developed economies such as the US and the UK, where unemployment remains a major concern. Barclays said the second half of the year is expected to continue to be challenging, but said impairments were expected to be below those in the first half, which were increased by £1.6bn in the second quarter to £3.7bn, and that its investment banking arm was “well positioned”. Lloyds, on the other hand, which does not have an investment bank, said investors should not expect a near term recovery for income. Like Barclays, it expects loan losses will also be less than the first half, guiding to a total of £4.5bn-£5.5bn, with stable net interest margin, costs below £7.6bn and risk-weighted assets flat to “slightly up” on the first half. “Lloyds is, by and large, a bread and butter bank,” said Nicholas Hyett, equity analyst at Hargreaves Lansdown. “It takes deposits and makes loans – cross selling wealth management, pension and insurance products on the side. Unfortunately it’s the core lending business which has been hit hardest by the current crisis.” With lower Bank of England interest rates squeezing loan profitability, together with a massive shift in the loan book away from profitable consumer lending and towards less lucrative commercial lending through government support schemes, Lloyds has little elbow room. “While some of the headwinds elsewhere in the bank, such as insurance sales, look set to diminish as lockdowns come to an end, and consumer borrowing should pick up too, the long term challenges of low interest rates and anaemic economic growth are probably here to stay for some time,” Hyett said. “These are hardly ideal conditions for Lloyds, in fact they’re pretty close to the perfect storm.” Glimmers of hope? Hunter said any glimmers of hope “are unfortunately few and far between” - pointing to the increased adoption of digital banking during lockdown plus the combined effort by the banks, government and Bank of England to encourage economic recovery, “and consign their chequered reputation to the history books” following their ignominious role in the global financial crisis, with banks are positioning themselves to be part of the solution rather than a large part of the problem. Lloyds itself has lent around £9bn through government-backed lending schemes, giving an additional 1.1mln payment holidays and 33,000 capital repayment holidays standing alongside. While the bank has a comfortable CET1 capital ratio of 14.6% and an as-yet unused PPI provision of £745mln, which could be released in part or in full after all claims have been settled, Hunter the results make for difficult reading. With an 8% fall to 26p on Thursday, Lloyds shares are down 59% so far in 2020, compared to a 45% fall for other mainstream UK banks and a 22% drop for the wider FTSE 100. This is indicative of the market trying to price in the sheer scale of the challenge which Lloyds faces, says Hunter. “Reasons for optimism on shorter-term prospects, it appears, will need to wait for another day. In the meantime, it remains to be seen whether the market consensus of the shares as a buy, and indeed having recently moved to being the preferred play in the sector, will come under some serious review.” Shore Cap's Greenwood offered a more optimistic view, suggesting the second quarter “represents an awful set of results, [but] we think this is could be a nadir in terms of quarterly profitability (excluding bank levy) with economic activity starting to improve and significant forward-looking provisions already set aside”. At the previous day's closing price of 28p, Lloyds traded on 0.54 times trailing tangible net asset value per share of 51.6p. Greenwood said he sees fair value at 43p, offering a potential 54% upside. “We would encourage investors to look through a very disappointing set of Q2 results and reflect on the strength of the balance sheet and scope for profits to improve materially in future as the economy recovers. “We think much of the bad news is already in the numbers and, more importantly, the share price.” [...]
xxxxxy: Pressure rises on HSBC in Hong Kong row as Aviva lashes out at bankCity investor says decision by HSBC and and Standard Chartered to back China's security law for the territory makes it "uneasy"ByLucy Burton, BANKING EDITOR9 June 2020 • 4:40pmOne of Britain's most powerful investors has hit out at HSBC and Standard Chartered for backing Beijing's crackdown on Hong Kong in a move that could pave the way for others to follow suit. The London-listed banks were last week condemned by democracy campaigners for supporting the law, which criminalises anti-government movements in Hong Kong. Both Britain and the US, where the majority of HSBC's investors are based, have called it a violation of Beijing's obligations to the territory. Investors stayed silent, however. hTtps://www.telegraph.co.uk/business/2020/06/09/aviva-first-investor-hit-hsbc-hong-kong-row/OJ Simpson9 Jun 2020 5:29PMReally disappointed with HSBC on this one. I hope they change course for the sake of their home market in the WestLikeReplyGordon Stuart9 Jun 2020 5:35PM@OJ SimpsonAll international banks will be doing the same. Little locals like Lloyds and RBS have almost no interest in the far east.Martin Hainsworth9 Jun 2020 5:25PMIf HSBC can not stand up to China (and there are commercial reasons that it can't), then it should demerge Midland Bank and list HSBC on the Hong Kong and Shanghai markets only. It should leave London....Maybe to taken over by Lloyds. Who knows. And there will be the USA. Who knows.
ADVFN Advertorial
Your Recent History
Lloyds Ban..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201127 01:13:28